$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040531 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$850.2K	$458.8K
YoY Change	182.39%	201.02%
% of Gross Profit
Research & Development	$432.6K	$1.140M
YoY Change	-1.61%	70.44%
% of Gross Profit
Depreciation & Amortization	$1.980K	$4.830K
YoY Change	32.89%	205.7%
% of Gross Profit
Operating Expenses	$1.283M	$1.599M
YoY Change	73.17%	94.67%
Operating Profit		-$1.599M
YoY Change		94.67%
Interest Expense	-$357.7K	-$150.2K
YoY Change	3434.39%	-70.3%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$193.6K
YoY Change		9.41%
Pretax Income	-$1.641M	-$1.775M
YoY Change	118.47%	77.81%
Income Tax
% Of Pretax Income
Net Earnings	-$1.641M	-$1.793M
YoY Change	118.47%	79.56%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.11
Diluted Earnings Per Share	-$0.10	-$0.11
COMMON SHARES
Basic Shares Outstanding	16.00M shares	15.73M shares
Diluted Shares Outstanding		1.970M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.464M	$6.807M
YoY Change	-35.09%	-25.37%
Cash & Equivalents	$2.576M	$3.886M
Short-Term Investments	$2.887M	$2.921M
Other Short-Term Assets	$114.5K	$6.480K
YoY Change	-28.97%	-96.03%
Inventory
Prepaid Expenses	$114.5K	$170.1K
Receivables	$14.90K	$12.44K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.593M	$6.996M
YoY Change	-34.8%	-24.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.83K	$26.81K
YoY Change	97.16%	90.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$358.7K	$380.2K
YoY Change	377.07%	310.9%
TOTAL ASSETS
Total Short-Term Assets	$5.593M	$6.996M
Total Long-Term Assets	$358.7K	$380.2K
Total Assets	$5.952M	$7.376M
YoY Change	-31.22%	-21.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$282.9K	$180.0K
YoY Change	142.28%	67.99%
Accrued Expenses	$163.4K	$167.6K
YoY Change	-5.81%	-5.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$596.0K	$462.8K
YoY Change
Total Short-Term Liabilities	$1.042M	$810.4K
YoY Change	6.82%	-16.49%
LONG-TERM LIABILITIES
Long-Term Debt	$135.1K	$134.4K
YoY Change
Other Long-Term Liabilities	$718.6K	$821.3K
YoY Change		12212.59%
Total Long-Term Liabilities	$853.7K	$955.6K
YoY Change		14227.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.042M	$810.4K
Total Long-Term Liabilities	$853.7K	$955.6K
Total Liabilities	$1.896M	$1.766M
YoY Change	94.32%	80.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.49M	-$13.85M
YoY Change	74.12%	70.03%
Common Stock	$161.00	$160.00
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.056M	$5.610M
YoY Change
Total Liabilities & Shareholders Equity	$5.952M	$7.376M
YoY Change	-31.22%	-21.38%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.641M	-$1.793M
YoY Change	118.47%	79.56%
Depreciation, Depletion And Amortization	$1.980K	$4.830K
YoY Change	32.89%	205.7%
Cash From Operating Activities	-$1.062M	-$1.539M
YoY Change	56.24%	46.49%
INVESTING ACTIVITIES
Capital Expenditures		$19.05K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$87.03K	-$7.710K
YoY Change
Cash From Investing Activities	$87.04K	-$26.76K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-334.4K	4.530K
YoY Change	1334.18%	-99.96%
NET CHANGE
Cash From Operating Activities	-1.062M	-1.539M
Cash From Investing Activities	87.04K	-26.76K
Cash From Financing Activities	-334.4K	4.530K
Net Change In Cash	-1.310M	-1.561M
YoY Change	86.24%	-117.21%
FREE CASH FLOW
Cash From Operating Activities	-$1.062M	-$1.539M
Capital Expenditures		$19.05K
Free Cash Flow		-$1.558M
YoY Change		48.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent		usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001757499
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	SHPH	Finance Fee FinanceFee		usd
CY2023Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022Q3	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
CY2022Q3	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2022Q3	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest StockIssuedDuringPeriodValueConversionOfAccruedInterest		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments		usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock		usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss		usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	SHPH	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
	SHPH	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	SHPH	Proceeds From Issuance Of Common Stock And Exercise Of Warrants ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest		usd
	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable		usd
	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable		usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees		usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41488
	dei	Entity Registrant Name EntityRegistrantName	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	401 Professional Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	403-4212
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	SHPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15999125	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3885997	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	170104	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	161148	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2920592	usd
CY2023Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	12435	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	6480	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6995608	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8578351	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26810	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12592	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6480	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	353400	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56122	usd
CY2023Q3	us-gaap	Assets Assets	7375818	usd
CY2022Q4	us-gaap	Assets Assets	8653545	usd
CY2023Q3	SHPH	Convertible Note Payable Current ConvertibleNotePayableCurrent	462825	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	61034	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	62823	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	810437	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	975676	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	134382	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	512825	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	308425	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1766069	usd
CY2022Q4	us-gaap	Liabilities Liabilities	975676	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15999125	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15999125	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13603129	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13603129	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	136	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19456701	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16572622	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13847112	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8894889	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5609749	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7375818	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8653545	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1140307	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	669038	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3084488	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1048821	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	170423	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81864	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	452342	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104711	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	288416	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	70566	usd
	us-gaap	Legal Fees LegalFees	1072728	usd
	us-gaap	Legal Fees LegalFees	659958	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1599146	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	821468	usd
	us-gaap	Operating Expenses OperatingExpenses	4609558	usd
	us-gaap	Operating Expenses OperatingExpenses	1813490	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1599146	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-821468	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4609558	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1813490	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	20765	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	56720	usd
	SHPH	Finance Fee FinanceFee	104245	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	442900	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	112797	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2118175	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	94025	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1744	usd
CY2023Q3	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	9606	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	21134	usd
CY2023Q3	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	43414	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	328687	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	328687	usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-193608	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-176957	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-342665	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1628132	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319643	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166533	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-681839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1849563	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-464049	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1775254	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-998425	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4952223	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2277539	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1792754	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-998425	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4952223	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2277539	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	19473	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	71009	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1792754	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1017898	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4952223	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2348548	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15744210	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10164979	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14554878	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9723510	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	99543	usd
CY2023Q1	SHPH	Financing Fees Allocated To Warrants FinancingFeesAllocatedToWarrants	-8727	usd
CY2023Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	104547	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8333	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2023Q2	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	2163992	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49522	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2184372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935610	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	429310	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37583	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1792754	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5609749	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166533	usd
CY2022Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	25768	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-597275	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2306073	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2306073	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10031415	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14098	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	92598	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	588524	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	576476	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23667	usd
CY2022Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	19473	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	402069	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-998425	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8404875	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8404875	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4952223	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2277539	usd
	us-gaap	Depreciation Depreciation	4828	usd
	us-gaap	Depreciation Depreciation	4484	usd
	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2118175	usd
	SHPH	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	94025	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1654724	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	885505	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1744	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	21134	usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	294927	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	328687	usd
	SHPH	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	73007	usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	-12625	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	95438	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	356733	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	12435	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5954	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8956	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	158276	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	63255	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-392473	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12500	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	106578	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	5727	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-98135	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	38286	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	9358	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3986	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4518973	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2030587	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2977714	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19046	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2916760	usd
	SHPH	Proceeds From Issuance Of Common Stock And Exercise Of Warrants ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants	10045513	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	685473	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	50000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	600715	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	345000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2904527	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10646228	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4531206	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8615641	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	504749	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3885997	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9120390	usd
	us-gaap	Interest Paid Net InterestPaidNet	102373	usd
	us-gaap	Interest Paid Net InterestPaidNet	17489	usd
	SHPH	Common Stock Issued For Conversion Of Accrued Interest CommonStockIssuedForConversionOfAccruedInterest	16340	usd
	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	2697849	usd
	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	588524	usd
	SHPH	Common Stock Issued For Exercise Of Warrants With Settlement Of Notes Payable CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable	576476	usd
	SHPH	Common Stock Issued For Dividend Payable CommonStockIssuedForDividendPayable	402067	usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	90816	usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability	365556	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4952223	usd
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10022193	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zOSo5OW6VSkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zQkQsrxaJZF1">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zLwaeE1cPJY8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z9hJ1dUsGCV">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying condensed consolidated financial statements for the valuation of derivatives, share-based compensation, useful lives for depreciation and amortization of long-lived assets, and the incremental borrowing rate used on right-of-use assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Cash	2867519	usd
CY2022Q4	us-gaap	Cash Cash	5411378	usd
CY2023Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1018478	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3005825	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3885997	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8417203	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3256000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2920592	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	56720	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	1744	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	21134	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	512825	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	83230	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	52631	usd
	us-gaap	Sublease Income SubleaseIncome	6377	usd
	us-gaap	Sublease Income SubleaseIncome	4949	usd
	us-gaap	Lease Cost LeaseCost	76853	usd
	us-gaap	Lease Cost LeaseCost	47682	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	73884	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2716035	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2716035	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20000	shares
	us-gaap	Lessee Operating Lease Assumptions And Judgments Discount Rate Description LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription	The interest rate used to determine the present value of our lease ending in October of 2023 was our incremental borrowing rate estimated at 10% when the lease was entered into in 2019. Our new lease beginning in June of 2023, the interest rate used was an equity built up, risk adjusted rate, estimated to be 10.48%, as the interest rate implicit in most of our leases is not readily determinable.
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The first is for a monthly payment of $6,480, with a security deposit of $6,480 held for the duration of the lease, and commenced on October 1, 2018, with the first payment made on January 1, 2019
	us-gaap	Payments For Rent PaymentsForRent	6480	usd
CY2023Q3	us-gaap	Deposits Deposits	6480	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2023Q1	SHPH	Common Area Maintenance Cost CommonAreaMaintenanceCost	3300	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	43234	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	3891	usd
	SHPH	Common Area Maintenance Cost CommonAreaMaintenanceCost	3315	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	56617	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365556	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y11M4D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y18D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1048	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2021Q4	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021 the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10000000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	538302	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1550479	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	2589300	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1992093	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	597207	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	502087	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2380996	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	0	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	839	shares
CY2022Q3	SHPH	Accrued Interest Value To Issue Shares AccruedInterestValueToIssueShares	0	usd
	SHPH	Accrued Interest Value To Issue Shares AccruedInterestValueToIssueShares	16340	usd
CY2022Q3	SHPH	Common Stock Vesting Of Restricted Stock Unit CommonStockVestingOfRestrictedStockUnit	1045	shares
	SHPH	Common Stock Vesting Of Restricted Stock Unit CommonStockVestingOfRestrictedStockUnit	11253	shares
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10031415	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10031415	usd
CY2022Q3	SHPH	Stock Issued During Period Value Settlement Notes Payable StockIssuedDuringPeriodValueSettlementNotesPayable	88524	usd
CY2022Q3	SHPH	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	2267551	shares
	SHPH	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	2267551	shares
CY2022Q3	SHPH	Stock Issued During Period Value Warrants Notes Payable StockIssuedDuringPeriodValueWarrantsNotesPayable	590574	usd
	SHPH	Stock Issued During Period Value Warrants Notes Payable StockIssuedDuringPeriodValueWarrantsNotesPayable	590574	usd
CY2022Q3	SHPH	Stock Issued During Period Shares Conversion Of Preferred Shares StockIssuedDuringPeriodSharesConversionOfPreferredShares	336810	shares
	SHPH	Stock Issued During Period Shares Conversion Of Preferred Shares StockIssuedDuringPeriodSharesConversionOfPreferredShares	336810	shares
	SHPH	Stock Issued During Period Shares Conversion Of Dividends StockIssuedDuringPeriodSharesConversionOfDividends	100517	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q3	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	410130	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1018079	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.35
CY2023Q1	SHPH	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Value ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue	1189000	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2631000	usd
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	512825	usd

Files In Submission

Name	View Source	Status
shph-20230930_cal.xml	Edgar Link	unprocessable
shph-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-040531-index-headers.html	Edgar Link	pending
0001493152-23-040531-index.html	Edgar Link	pending
0001493152-23-040531.txt	Edgar Link	pending
0001493152-23-040531-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20230930.xsd	Edgar Link	pending
shph-20230930_lab.xml	Edgar Link	unprocessable
shph-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q4 Form 10-Q Financial Statement

#000149315223040531 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2023 Q4 Form 10-Q Financial Statement

#000149315223040531 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph